

Express Mail Label No.

Dated: _____

Docket No.: 09857/0202181-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jenny Nyberg et al.

Application No.: 10/518,159

Confirmation No.: 7593

Filed: January 18, 2005

Art Unit: N/A

For: USE OF COMPOUNDS HAVING GIP
ACTIVITY FOR THE TREATMENT OF
DISORDERS ASSOCIATED WITH
ABNORMAL LOSS OF CELLS AND/OR
FOR THE TREATMENT OF OBESITY

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 31, 2006

Respectfully submitted,

By  *Jason Chumney*
(53,970)

Jason C. Chumney

Registration No.: 54,781

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/518,159-Conf. #7593	
			Filing Date	January 18, 2005	
			First Named Inventor	Jenny Nyberg	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	09857/0202181-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	DE-199 21 537-A	11-23-2000	Hoersch Dieter		
	BB	WO-00 58360-A3	10-05-2000	Univeristy of Ulster		
	BC	EP-0 479 210-B1	04-08-1992	Sanwa Kagaku Kenkyusho		
	BD	WO-98 24464-A1	06-11-1998	Trustees of Boston University		
	BE	EP-0 186 181-A2	07-02-1986	Syntec (U.S.A.) Inc.		
	BF	WO-03 030946-A	04-01-2003	Novertis AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	"Derwent WPI" Section Ch, Week 199320, Derwent Publications Ltd., London, B, Class A 96, AN 1993-164366.	
	CB	"Recepteurs illicites dans le syndrome de Cushing surrenalien", LACROIX, Annales d'Endocrinologie, 2001, 62, 2, pp. 185-188.	
	CC	"Glucose-Dependent Insulinotropic Polypeptide is a Growth Factor for β (INS-1) Cells by Pleiotropic Signaling", TRUMPER et al., Molecular Endocrinology 15(9), pp. 1559-1570.	
	CD	"Gastic Inhibitory Polypeptide (GIP) Binding Sites in Rat Brain", KAPLAN et al., Peptides, Vol. 15, No. 2, pp. 297-302, 1994.	
	CE	"The Identification of glucose insulinotropic polypeptide (GIP) in rat sensory ganglia and its regulation by somatostatin", COLE et al., Regulatory Peptides, Vol. 102, No. 1, October 15, 2001, pp. 52.	
	CF	"Immunohistochemical investigations of neuropeptides in the brain, corpora cardiaca, and corpora allata of an adult lepidopteran insect, <i>Manduca sexta</i> (L)", Cell and Tissue Research (1983) 232, pp. 295-317.	
	CG	"Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects", BOLLAG et al., Molecular and Cellular Endocrinology 177 (2001), pp. 35-41.	
	CH	"Gastric Inhibitory Polypeptide (GIP) in Anorexia Nervosa", DIXON et al., The International Journal of Eating Disorders, Vol. 4, No. 4, November 1985, pp. 597-604.	
	CI	International Search Report for PCT/EP03/06207 mailed March 24, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--